Unique ID issued by UMIN | UMIN000008261 |
---|---|
Receipt number | R000009707 |
Scientific Title | Evaluation of efficacy in endoscopic submucosal dissection to early gastric cancer, early esophageal cancer, and/or early pharyngeal cancer by new device "Nanoshooter". |
Date of disclosure of the study information | 2012/06/26 |
Last modified on | 2022/07/04 09:27:18 |
Evaluation of efficacy in endoscopic submucosal dissection to early gastric cancer, early esophageal cancer, and/or early pharyngeal cancer by new device "Nanoshooter".
Evaluation of efficacy in endoscopic submucosal dissection to early gastric cancer, early esophageal cancer, and/or early pharyngeal cancer by new device "Nanoshooter".
Evaluation of efficacy in endoscopic submucosal dissection to early gastric cancer, early esophageal cancer, and/or early pharyngeal cancer by new device "Nanoshooter".
Evaluation of efficacy in endoscopic submucosal dissection to early gastric cancer, early esophageal cancer, and/or early pharyngeal cancer by new device "Nanoshooter".
Japan |
early gastric cancer (gastric adenoma)
early esophageal cancer
early pharyngeal cancer
Gastroenterology |
Malignancy
NO
In comparison with underlying disease, old person, patient with the risk factor or ESD enforcement patient who does not hope for anesthesia, we evaluate efficacy and safety of nasal-ESD using new device "Nanoshooter" for early gastric cancer(gastric glands tumor), early esophageal cancer, and/or early pharyngeal cancer.
Safety,Efficacy
Efficacy
1)Efficacy in nasal endoscopic submucosal dissection by oral way to early gastric cancer and/or early esophageal cancer.
2)Efficacy in nasal endoscopic submucosal dissection by nasal way to early gastric cancer, early esophageal cancer, and/or early pharyngeal cancer.
Safety
Treatment time, bleeding, a ratio of perforation, Visual Analog Scale
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Device,equipment |
Nanoshooter (Top)
18 | years-old | <= |
90 | years-old | > |
Male and Female
The inclusion criteria.
1)The patient's age is between 18 and 89 years old.
2)The patient who has diagnosis of early gastric cancer, gastric adenoma, early esophageal cancer, and/or early pharyngeal cancer.
3)Informed Consent.
4)Hospitalization.
5)The patient that contraception is possible during the study.
The exclusion criteria.
1)The patient who repeats hematemesis.
2)The patient who has a history of allergy to the use drug.
3)The patient that the withdrawal of coagulant and/or antiplatelet agent is impossible.
4)The patient with bad physical status.
5)The patient who cannot do to informed consent.
6)The patient who was considered ineligible by the investigators.
75
1st name | |
Middle name | |
Last name | Masakatsu Nakamura |
Kanazawa Medical University
Department of Gastroenterology
1-1 Daigaku, Uchinada, Kahoku, Ishikawa
1st name | |
Middle name | |
Last name | Masakatsu Nakamura |
Kanazawa Medical University
Department of Gastroenterology
1-1 Daigaku, Uchinada, Kahoku, Ishikawa
Kanazawa Medical University
Kanazawa Medical University
Self funding
NO
2012 | Year | 06 | Month | 26 | Day |
Unpublished
Completed
2012 | Year | 04 | Month | 02 | Day |
2012 | Year | 05 | Month | 23 | Day |
2012 | Year | 07 | Month | 01 | Day |
2021 | Year | 06 | Month | 25 | Day |
2012 | Year | 06 | Month | 26 | Day |
2022 | Year | 07 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009707